Last C$1.50 CAD
Change Today -0.15 / -9.09%
Volume 1.2K
As of 1:37 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

helix biopharma corp (HBP) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/10/14 - C$2.27
52 Week Low
02/7/14 - C$1.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HELIX BIOPHARMA CORP (HBP)

Related News

No related news articles were found.

helix biopharma corp (HBP) Related Businessweek News

No Related Businessweek News Found

helix biopharma corp (HBP) Details

Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company focuses on the development of L-DOS47 that is in phase I/II clinical trial for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. It also offers DOS47, a patented oncology platform technology that derives a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. Helix BioPharma Corp. is headquartered in Aurora, Canada.

11.5 Employees
Last Reported Date: 10/23/14

helix biopharma corp (HBP) Top Compensated Officers

Chief Executive Officer, President, Non-Indep...
Total Annual Compensation: C$325.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$260.0K
Chief Scientific Officer
Total Annual Compensation: C$275.0K
Compensation as of Fiscal Year 2014.

helix biopharma corp (HBP) Key Developments

Helix Biopharma Corp. Announces Initiation of First Clinical Site for US Study

Helix BioPharma announced that its United States Phase I study of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous non-small cell lung cancer has been initiated at The University of Texas MD Anderson Cancer Center in Houston, Texas. Helix also anticipates the participation of two additional sites in the United States. Helix anticipates that the first patient will be enrolled in the LDOS001 study in the first quarter of 2015. LDOS001 is a Phase I, open label, dose escalation study of the company's lead product L-DOS47. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/carboplatin. The study will also evaluate the potential clinical benefit of L-DOS47 with this combination. Other exploratory objectives include the evaluation of the L-DOS47 pharmacokinetics and immunogenicity.

Helix Biopharma Corp. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended October 31, 2014

Helix Biopharma Corp. announced unaudited consolidated earnings results for the first quarter ended October 31, 2014. The Company recorded a net loss and total comprehensive loss of $2,125,000 or $0.03 loss per common share and $2,137,000 or $0.03 loss per common share for the three-month periods ended October 31, 2014 and 2013, respectively. Cash used in operating activities was $2,153,000 against $2,027,000 a year ago.

Helix Biopharma Seeks Acquisitions

Helix Biopharma Corp. (TSX:HBP) is seeking acquisitions. Helix Biopharma said, “Growth opportunities the Company may pursue could include, but are not limited to, partnering or other collaboration agreements or the acquisition of some or all of another company's business or assets.” Cantor Fitzgerald & Co. has been engaged by Helix Biopharma to assist in exploring growth opportunities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HBP:CN C$1.50 CAD -0.15

HBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HBP.
View Industry Companies

Industry Analysis


Industry Average

Valuation HBP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 23.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HELIX BIOPHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at